613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)

Bibliographic Details
Main Authors:	Fiore Cattaruzza, Ayesha Nazeer, Zachary Lange, Caitlin Koski, Mikhail Hammond, Trang Dao-Pick, Angela Henkensiefken, Mika Derynck, Volker Schellenberger, Bryan Irving
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

id	doaj-251cfc5cf7644032b9a3fd31021d0f8c
record_format	Article
spelling	doaj-251cfc5cf7644032b9a3fd31021d0f8c2020-12-11T10:04:57ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0613613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)Fiore Cattaruzza0Ayesha Nazeer1Zachary Lange2Caitlin Koski3Mikhail Hammond4Trang Dao-Pick5Angela Henkensiefken6Mika Derynck7Volker Schellenberger8Bryan Irving9Amunix, San Francisco, CA, USAAmunix, San Francisco, CA, USAAmunix, San Francisco, CA, USAAmunix, San Francisco, CA, USAAmunix, San Francisco, CA, USAAmunix, San Francisco, CA, USAAmunix, San Francisco, CA, USAAmunix, San Francisco, CA, USAAmunix, San Francisco, CA, USAAmunix, San Francisco, CA, USA
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Fiore Cattaruzza Ayesha Nazeer Zachary Lange Caitlin Koski Mikhail Hammond Trang Dao-Pick Angela Henkensiefken Mika Derynck Volker Schellenberger Bryan Irving
spellingShingle	Fiore Cattaruzza Ayesha Nazeer Zachary Lange Caitlin Koski Mikhail Hammond Trang Dao-Pick Angela Henkensiefken Mika Derynck Volker Schellenberger Bryan Irving 613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP) Journal for ImmunoTherapy of Cancer
author_facet	Fiore Cattaruzza Ayesha Nazeer Zachary Lange Caitlin Koski Mikhail Hammond Trang Dao-Pick Angela Henkensiefken Mika Derynck Volker Schellenberger Bryan Irving
author_sort	Fiore Cattaruzza
title	613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)
title_short	613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)
title_full	613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)
title_fullStr	613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)
title_full_unstemmed	613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)
title_sort	613 her2-xpat, a novel protease-activatable prodrug t cell engager (tce), with potent t-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (nhp)
publisher	BMJ Publishing Group
series	Journal for ImmunoTherapy of Cancer
issn	2051-1426
publishDate	2020-11-01
work_keys_str_mv	AT fiorecattaruzza 613her2xpatanovelproteaseactivatableprodrugtcellengagertcewithpotenttcellactivationandefficacyinsolidtumorsandlargepredictedsafetymarginsinnonhumanprimatenhp AT ayeshanazeer 613her2xpatanovelproteaseactivatableprodrugtcellengagertcewithpotenttcellactivationandefficacyinsolidtumorsandlargepredictedsafetymarginsinnonhumanprimatenhp AT zacharylange 613her2xpatanovelproteaseactivatableprodrugtcellengagertcewithpotenttcellactivationandefficacyinsolidtumorsandlargepredictedsafetymarginsinnonhumanprimatenhp AT caitlinkoski 613her2xpatanovelproteaseactivatableprodrugtcellengagertcewithpotenttcellactivationandefficacyinsolidtumorsandlargepredictedsafetymarginsinnonhumanprimatenhp AT mikhailhammond 613her2xpatanovelproteaseactivatableprodrugtcellengagertcewithpotenttcellactivationandefficacyinsolidtumorsandlargepredictedsafetymarginsinnonhumanprimatenhp AT trangdaopick 613her2xpatanovelproteaseactivatableprodrugtcellengagertcewithpotenttcellactivationandefficacyinsolidtumorsandlargepredictedsafetymarginsinnonhumanprimatenhp AT angelahenkensiefken 613her2xpatanovelproteaseactivatableprodrugtcellengagertcewithpotenttcellactivationandefficacyinsolidtumorsandlargepredictedsafetymarginsinnonhumanprimatenhp AT mikaderynck 613her2xpatanovelproteaseactivatableprodrugtcellengagertcewithpotenttcellactivationandefficacyinsolidtumorsandlargepredictedsafetymarginsinnonhumanprimatenhp AT volkerschellenberger 613her2xpatanovelproteaseactivatableprodrugtcellengagertcewithpotenttcellactivationandefficacyinsolidtumorsandlargepredictedsafetymarginsinnonhumanprimatenhp AT bryanirving 613her2xpatanovelproteaseactivatableprodrugtcellengagertcewithpotenttcellactivationandefficacyinsolidtumorsandlargepredictedsafetymarginsinnonhumanprimatenhp
_version_	1724386429171138560

613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)

Similar Items